Summary Patients with invasive cancer of the breast (TI-4, MO) 
Previous studies have demonstrated the excellent reduction in size of primary breast cancer achieved by chemotherapy (Delena et al., 1981; Swain et al., 1987; Perloff et al., 1988) and endocrine therapy (Smith et al., 1993 , Forrest et al., 1986 .
A randomised trial of primary chemotherapy in patients with advanced primary breast carcinoma has shown that it is more effective in rapidly reducing the size of the primary lesion than endocrine therapy (P= 0.001) and that it significantly alters the future management of these patients (Gazet et al., 1991) . Despite screening, a high proportion of patients still present with T3 or T4 breast carcinoma requiring mastectomy. For this reason we have evaluated the role of neoadjuvant therapy with particular regard to the role of oestrogen receptor (ER) determination by immunocytochemistry using oestrogen receptor immunocytochemical assay (ERICA) as in those patients in which the ER was not evaluated before treatment only 10% responded to endocrine therapy (Gazet et al., 1991) .
We hypothesised that endocrine therapy might have a role in neoadjuvant therapy of breast cancer, provided that the ERICA could be performed in the primary tumours, thus indicating which tumours were hormone sensitive.
Patients, materials and methods
This trial included a series of consecutive patients aged between 30 and 69 (mean 54.02) attending the Combined Breast Clinic at St. George's Hospital between 1990 and 1993 who had a clinical carcinoma of the breast, T -T4 NO, NI or N2. This was confirmed by mammographic and fine needle aspiration cytology (FNAC) with no evidence of metastases on standard screening (Coombes et al., 1980) , which included chest radiograph, bone scan, liver ultrasound, full blood picture and liver function tests.
All patients were fully informed of the object of the trial. (Table I ). In the group T1/T2, 86% (62) had a wide local excision, 3% (two) had a mastectomy and 11% (eight) were treated by radiotherapy. In the T3/T4 group, 42% (11) had a wide local excision, 35% (nine) had a mastectomy and 23% (six) were treated by radiotherapy. There were two treatment violations.
Histological assessment after treatment A detailed study of the histopathological changes associated with pretreatment has been made and will be reported elsewhere (Corbishley et al., 1996 The post-therapy breast tissue specimens were X-rayed with the localisation wire in situ, serially sliced at 4 mm intervals and extensively sampled. Sixteen showed invasive carcinoma (Figure 1 ). In three patients no residual tumour cells were identified (Figure 2 ). Seven patients showed foci of invasive tumour less than 10 mm in maximum dimensions (range 1-8 mm) (Figure 3) . The remaining nine patients showed tumour masses ranging from 10 to 70 mm. The largest residual tumour mass was a widely infiltrating lobular carcinoma with no histological evidence of tumour regression (Figure 4 ). Two patients with proven invasive ductal carcinoma on Trucut biopsy showed residual widespread ductal carcinoma in situ only (35 mm and 25 mm respectively) ( Figure 5 ).
In all, 78 post treatment specimens were available for tumour assessment. There were two violations, six refused surgery and 14 were treated by radiotherapy (Table II) .
In those patients showing histological evidence of tumour (Tables IV and V) . Owing to our familiarity with MMM regimen, we chose it as the chemotherapeutic combination for our ER-negative patients. The chemotherapeutic combination of mitozantrone, methotrexate and mitomycin C (3M) was devised as first-line treatment for disseminated breast cancer in 1987 by Powles et al. (1991) . Subsequent studies have shown that 3M compares favourably with vincristine, anthracyclines (doxorubicin or epirubicin) and cyclophosphamide (VA) having significantly less symptomatic toxicity through greater myelosuppression in the management of advanced breast cancer (Powles et al., 1991) and has an efficacy and toxicity spectrum very similar to cyclophosphamide, methotrexate and 5-fluorouracil (5-FU) (CMF) (Jodrell et al., 1991) .
Leuprolide, an LHRH agonist in premenopausal patients with a major effect via ovarian suppression (Nicholson et al., 1985 , Dixon et al., 1990 ) and formestane (4-hydroxyandrostenedione), an aromatase inhibitor in oestrogen synthesis in postmenopausal women (Stein et al., 1990) were used in preference to tamoxifen in an attempt to facilitate assessment at 3 months, as tamoxifen, in our experience, can cause tumour flare and also takes longer to achieve a response (Gazet et al., 1994) .
The results of this pilot study suggested that 60% of patients treated with chemotherapy had a clinical reduction in the size of their tumour at 12 weeks compared with 44% receiving endocrine treatment. This is in part due to the welldocumented fact that endocrine treatment will take longer to be effective and our cut-off point was 3 months (Gazet et al., 1994) . There were two important clinical implications. Firstly, a significantly greater proportion of patients had conservative surgery. Secondly, the degree of reduction in size achieved by primary chemotherapy may well reflect the sensitivity of micrometastases to systemic chemotherapy and thus could be a highly significant prognostic feature in patients with breast cancer. This has confirmed the results of previous nonrandomised trials using chemotherapy alone (Hortobagyi et al., 1991) or with radiotherapy and endocrine therapy (Rubens et al., 1992) . However, although 25 patients (25%) had a complete clinical resolution of their primary tumour, the radiological assessment showed an average mammographic reduction in size by 78% and on ultrasound by 85%.
The importance of the residual mass requires further interpretation as to its significance (Stein et al., 1990) . The fact that residual tumour was present in 16 of 19 specimens examined suggests the former, and confirms the importance of surgical excision and thorough pathological assessment after neoadjuvant therapy. Six patients who had a complete clinical response having refused surgery, accepted radiotherapy treatment to the breast. To date one has had local recurrence and a mastectomy.
Although the literature on chemotherapy in breast cancer is extensive there is no report of a randomised trial on pretreatment with chemotherapy or endocrine therapy on TI -T4 tumours based on ER status of the primary cancer. Anderson et al. (1991) , in a non-randomised trial of patients with tumours greater than 4 cm, noted a 39% response (24 61) in patients receiving endocrine therapy only, with one complete remission, whereas there was a significant reduction in 72% (34/47) patients receiving CHOP (cyclophosphamide 1 gm-2, doxorubicin 50 mg m-2, vmcristine 1.4 mg m-2 with oral prednisolone 40 mg per day for 5 days). Thirteen (27.6%) had a complete regression. Others (Bonadonna et al., 1990) In premenopausal women with advanced breast cancer LHRH agonists will reduce serum oestradiol levels to the equivalent of the menopause or surgical oophorectomy (Dixon et al., 1990) . These agents have an indirect action by reducing peripheral hormones rather than acting directly on LHRH receptors on the tumour (Harris et al., 1989) . Toxicity has been limited to hot flushes on either 3.75 or 7.5 mg i.m.i., once every 4 weeks ). In post-menopausal patients the response to LHRH agonists has varied from no objective response (Crighton et al., 1989) to 20% (Plowman et al., 1986) .
From its first use in 1984 (Coombes et al., 1984) , formestane has been an effective agent in post-menopausal patients with breast cancer and far more effective than aminoglutethmide. Reports have suggested a 27% response and 19% stabilisation in advanced breast cancer (Goss et al., 1986) . The median remission was 12 months in 33% of patients (14) and stabilisation in a further 14%. Ninety per cent of patients suffered no side-effects (Cunningham et al., 1987) and the drug is effective by both the intramuscular (Goss et al., 1986) and oral routes (Cunningham et al., 1987) . For all these reasons we chose formestane as the treatment for post-menopausal patients in this study. A recent study of post-menopausal women with advanced breast cancer (Mauriac et al., personal communication) , in which more than 400 patients were randomised to received either tamoxifen or formestane, has shown similar response rates of side-effects in both arms of the study.
Thus, in conclusion, there is strong evidence that appropriate pretreatment of breast cancer with chemotherapy or endocrine therapy according to the oestrogen receptor status will downgrade the tumour, increasing the opportunity for more conservative surgery.
